Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma

被引：7
|
作者：
Serrao, Alessandra [1 ]
Canichella, Martina [1 ]
De Luca, Maria Lucia [1 ]
Tartaglia, Germana [1 ]
Annechini, Giorgia [1 ]
D'Elia, Gianna Maria [1 ]
Pulsoni, Alessandro [1 ]
机构：
[1] Sapienza Univ Rome, Dept Cellular Biotecnol & Hemathol, Via Benevento 6, I-00161 Rome, Italy
来源：
ANNALS OF HEMATOLOGY | 2019年 / 98卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; MULTICENTER;
D O I：
10.1007/s00277-018-3541-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1505 / 1506
页数：2
相关论文
共 50 条
  • [31] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
    Bekoz, Huseyin
    Ozbalak, Murat
    Karadurmus, Nuri
    Paydas, Semra
    Turker, Alev
    Toptas, Tayfur
    Tuglular, Tulin Firatli
    Altuntas, Fevzi
    Cakar, Merih Kizil
    Sonmez, Mehmet
    Gulbas, Zafer
    Demir, Nazli
    Kaynar, Leylagul
    Yildirim, Rahsan
    Karadogan, Ihsan
    Arat, Mutlu
    Kapucu, Irem
    Aslan, Nevin Alayvaz
    Ozkocaman, Vildan
    Turgut, Mehmet
    Yuksel, Meltem Kurt
    Ozcan, Muhit
    Hacioglu, Sibel Kabukcu
    Barista, Ibrahim
    Demirkaya, Metin
    Saydam, Guray
    Toprak, Selami K.
    Yilmaz, Mehmet
    Demirkol, Onur
    Ferhanoglu, Burhan
    ANNALS OF HEMATOLOGY, 2020, 99 (11) : 2565 - 2576
  • [32] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
    Bekoz, H.
    Karadurmus, N.
    Paydas, S.
    Turker, A.
    Toptas, T.
    Tuglular, T. Firatli
    Sonmez, M.
    Gulbas, Z.
    Tekgunduz, E.
    Kaya, A. H.
    Ozbalak, M.
    Tastemir, N.
    Kaynar, L.
    Yildirim, R.
    Karadogan, I.
    Arat, M.
    Tanrikulu, F. Pepedil
    Ozkocaman, V.
    Abali, H.
    Turgut, M.
    Yuksel, M. Kurt
    Ozcan, M.
    Dogu, M. H.
    Hacioglu, S. Kabukcu
    Barista, I.
    Demirkaya, M.
    Koseoglu, F. D.
    Toprak, S. K.
    Yilmaz, M.
    Demirkurek, H. C.
    Demirkol, O.
    Ferhanoglu, B.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2496 - 2502
  • [33] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
    Huseyin Bekoz
    Murat Ozbalak
    Nuri Karadurmus
    Semra Paydas
    Alev Turker
    Tayfur Toptas
    Tülin Firatli Tuglular
    Fevzi Altuntas
    Merih Kizil Cakar
    Mehmet Sonmez
    Zafer Gulbas
    Nazlı Demir
    Leylagul Kaynar
    Rahsan Yildirim
    Ihsan Karadogan
    Mutlu Arat
    Irem Kapucu
    Nevin Alayvaz Aslan
    Vildan Ozkocaman
    Mehmet Turgut
    Meltem Kurt Yuksel
    Muhit Ozcan
    Sibel Kabukcu Hacioglu
    Ibrahim Barista
    Metin Demirkaya
    Guray Saydam
    Selami K. Toprak
    Mehmet Yilmaz
    Onur Demirkol
    Burhan Ferhanoglu
    Annals of Hematology, 2020, 99 : 2565 - 2576
  • [34] Paraneoplastic refractory prurigos in a Hodgkin lymphoma patient
    Okamura, Ikue
    Tatara, Raine
    Ikeda, Takashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (12) : 1179 - 1180
  • [35] Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
    Herbaux, Charles
    Gauthier, Jordan
    Brice, Pauline
    Fornecker, Luc
    Bouabdallah, Krimo
    Manson, Guillaume
    Ghesquieres, Herve
    Thiebaut-Bertrand, Anne
    Demarquette, Helene
    Boyle, Eileen
    Ysebaert, Loic
    Houot, Roch
    Yakoub-Agha, Ibrahim
    Morschhauser, Franck
    BLOOD, 2015, 126 (23)
  • [36] Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naive patients
    Lepik, Kirill V.
    Mikhailova, Natalia B.
    Moiseev, Ivan S.
    Kondakova, Elena V.
    Tsvetkova, Luibov A.
    Zalyalov, Yuri R.
    Borzenkova, Evgeniya S.
    Babenko, Elena V.
    Baykov, Vadim V.
    Markova, Inna V.
    Afanasyev, Boris V.
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2316 - 2319
  • [37] Efficiency of Nivolumab in Children with Refractory and Relapsed Hodgkin's and Non-Hodgkin's Lymphoma
    Kozlov, A.
    Iukhta, T.
    Gevorgian, A.
    Kazantzev, I.
    Tolkunova, P.
    Tsvetkova, L.
    Morozova, E.
    Lepik, K.
    Mikhailova, N.
    Zubarovskaya, L.
    Afanasyev, B.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S202 - S203
  • [38] ASHAP: AN EFFECTIVE SALVAGE THERAPY FOR REFRACTORY HODGKIN LYMPHOMA
    Cakir, F. B.
    Ozulker, T.
    Ozturk, G.
    PEDIATRIC BLOOD & CANCER, 2011, 56 (05) : 890 - 890
  • [39] Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma
    Dave, Hema
    Terpilowski, Madeline
    Mai, Mimi
    Toner, Keri
    Grant, Melanie
    Stanojevic, Maja
    Lazarski, Christopher
    Shibli, Abeer
    Bien, Stephanie A.
    Maglo, Philip
    Hoq, Fahmida
    Schore, Reuven
    Glenn, Martha
    Hu, Boyu
    Hanley, Patrick J.
    Ambinder, Richard
    Bollard, Catherine M.
    BLOOD ADVANCES, 2022, 6 (02) : 473 - 485
  • [40] Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review
    Macapagal, Sharina C.
    Lee, Hayoung
    Jabbar, Javaria Abdul
    Fjorden, Anna Caroline
    Joseph, Irene Tresa
    Kaur, Ramanpreet
    Mostafa, Jihan A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
12345